General Information
Palbociclib is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
About the API
Trade name(s)
Ibrance
Technology
Synthetic
Molecular Formula
C24H29N7O2
Molecular Weight
447.533 g/mol
Therapeutic category
Oncology
Available formulations
Oral Solid
Regulations
US DMF